Excelsior Biopharma (ROCO:6496) Total Liabilities : NT$622.6 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma Total Liabilities?

Excelsior Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 was NT$622.6 Mil.

Excelsior Biopharma's quarterly Total Liabilities declined from Sep. 2023 (NT$816.80 Mil) to Dec. 2023 (NT$472.87 Mil) but then increased from Dec. 2023 (NT$472.87 Mil) to Mar. 2024 (NT$622.61 Mil).

Excelsior Biopharma's annual Total Liabilities declined from Dec. 2021 (NT$608.90 Mil) to Dec. 2022 (NT$507.53 Mil) and declined from Dec. 2022 (NT$507.53 Mil) to Dec. 2023 (NT$472.87 Mil).

Excelsior Biopharma Total Liabilities Historical Data

The historical data trend for Excelsior Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma Total Liabilities Chart

Excelsior Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

244.06

617.15

608.90

507.53

472.87

Excelsior Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															513.22	503.26	816.80	472.87	622.61

Excelsior Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Excelsior Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	166.284	+	(300.25	+	3.1974423109205E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	6.34)
	=	472.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1577.328	-	1104.454
	=	472.9

Excelsior Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	223.85	+	(392.417	+	-2.4868995751604E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	6.34)
	=	622.6

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1685.863	-	1063.256
	=	622.6

Excelsior Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Excelsior Biopharma (ROCO:6496) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, 14th Floor-6, Nangang District, Taipei, TWN, 11503

Website

http://www.excelsiorgroup.com.tw

Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, research of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma (ROCO:6496) Headlines

No Headlines